Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

In November 2023, the FDA approved SpringWorks’ oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), for treating adult patients with progressing desmoid tumors who require systemic treatment.

The company reported its third quarter 2024 financial results, highlighting significant achievements including net product revenue of $49.3 million from its drug OGSIVEO and the FDA’s Priority Review ...

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non-cancerous tumour that ...

SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...